Neuropharmagen Core is a genetic test that helps to identify the safest and most suitable medication for each individual, thereby leading to quicker patient stabilization.
Identifying these parameters and knowing that there may be a better alternative at the beginning of a long treatment of a psychiatric patient makes this genetic marker test a therapeutic tool too good to ignore it.
Vega M. Psiquiatria.com. 2012; 16:5.
LGF is a 40 year-old woman with a schizoid-affective disorder. She had a poor response to treatment with poor metabolism. After being analyzed at her psychiatrist’s suggestion with Neuropharmagen, the results allowed her doctor to improve her treatment in accordance with her genetic profile: in this case, the prescribed dosage of Seroquel and Citalopram were increased.
The data provided by the test results in a series of recommendations and guidelines that help doctors select the most appropriate medication and thus manage to stabilize the patient.
- Doctors have changed treatment in 8 out of 10 patients in response to the results of Neuropharmagen testing and 83% of patients have noticed an improvement following the change of treatment.
- 91% of physicians consider applying Neuropharmagen on their patients is helpful and 96% intend to continue to use Neuropharmagen.